Malte Peters

Directeur Général chez TANGO THERAPEUTICS, INC. Fortune : 351 675 $ au 30/06/2026

Profil

Malte Peters is currently Chief Executive Officer & Director at HOOKIPA Pharma, Inc. since 2024.
Since 2018, holds the positions of President, Chief Executive Officer & Director at Tango Therapeutics, Inc., Director at Tango Therapeutics Sub, Inc., Director-Cancer Research at Merck KGAA Unsponsored ADR Facility, and Research Scientist at Amgen NV.
Formerly Chief Executive Officer & Director at Hookipa Biotech AG in 2024.
Served as Director-Cancer Research at Merck KGaA from 2003 to 2004 and Medical Director at Micromet AG during the same period.
From 2004 to 2015, was Head-Clinical, Site Head-Basel & East Hanover at Novartis AG.
From 2015 to 2017, was Global Head-Clinical Development at Sandoz International GmbH.
From 2020 to 2022, was Chief Research & Development Officer at MorphoSys AG.
Education includes a doctorate from Freie Universität Berlin.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
TANGO THERAPEUTICS, INC. 0,01 %	01/04/2026	11 250 ( 0,01 % )	351 675 $	30/06/2026

Postes actifs de Malte Peters

Sociétés	Poste	Début
TANGO THERAPEUTICS, INC.	Directeur Général	08/01/2026
HOOA PHARPAR	Directeur Général	22/07/2024
Tango Therapeutics Sub, Inc.	Directeur/Membre du Conseil	10/10/2018
Amgen NV	Corporate Officer/Principal	-
Merck KGAA Unsponsored ADR Facility	Corporate Officer/Principal	-

Anciens postes connus de Malte Peters

Sociétés	Poste	Fin
Hookipa Biotech AG	Directeur Général	18/11/2024
MORPHOSYS AG	Directeur Technique/Scientifique/R&D	01/10/2022
Sandoz International GmbH	Corporate Officer/Principal	01/02/2017
NOVARTIS AG	Directeur Technique/Scientifique/R&D	01/05/2015
░░░░░░░░ ░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░	░░░░░░░░░░